Clinical improvements in vision and cognition linked to the use of treatment candidate CNM-Au8 were correlated with signs of nerve cell repair and remyelination among people with relapsing-remitting multiple sclerosis (RRMS), according to new data. Remyelination is the process by which myelin, the fatty substance surrounding nerve cells…
Sanofi‘s oral BTK inhibitor tolebrutinib significantly delayed the onset of six-month confirmed disability progression compared with a placebo, by 31%, in people with nonrelapsing secondary progressive multiple sclerosis (SPMS). That’s according to recently published data from the HERCULES Phase 3 trial (NCT04411641), where the experimental therapy…
When I learned to cook, I didn’t attend a class or have formal lessons. I learned the basics as a child from my mother in our home kitchen. At first, everything was structured: follow the recipe to the letter, precisely measure everything, and use only the recommended tools for a…
A Phase 4 observational study called ENABLE is enrolling adults with relapsing forms of multiple sclerosis (MS) across the U.S. to better understand the safety, tolerability, and efficacy of Briumvi (ublituximab-xiiy) in the real world. At least 500 patients are expected to enter ENABLE (NCT06433752) at some…
A new artificial intelligence (AI) tool called MindGlide can accurately calculate, from a single MRI scan, multiple aspects of brain damage related to multiple sclerosis (MS) — even when employed with routine scans that are not typically used to monitor such damage. The development and validation of the tool…
I remember the day of my relapsing-remitting multiple sclerosis diagnosis, when I didn’t understand the weight of what I’d been told. I was only 17 years old and didn’t know what questions to ask, what the future held, or what I should’ve felt after hearing those words. Aside from feeling…
People with multiple sclerosis (MS) in Austria spend an average of €136 (about $149) per month on nondrug therapies such as dietary supplements and therapeutic interventions like physiotherapy, a study found. These complementary and alternative medicines (CAMs) are generally not fully covered by Austria’s public healthcare system, leaving many…
April showers bring May flowers. However, I do not have a green thumb. No matter how hard I try, I continuously seem to murder my plants. My mom, on the other hand, is an avid gardener. When my plants show signs of distress, I take them to her for remedial…
MS Canada is calling on everyone across Canada to tune up their bikes and join one of the many MS Bike rides this coming summer to help raise funds for research, advocacy, and support programs on behalf of people with multiple sclerosis (MS). With distances ranging from…
People of Asian descent tend to be younger than white people when they first exhibit symptoms of multiple sclerosis (MS), a U.S. study reports. Asians also tended to be younger at the time of their diagnosis. No differences were found in demographics or disease characteristics between Asian patients…
Treatment during pregnancy with the approved multiple sclerosis (MS) medication Copaxone (glatiramer acetate injection) does not appear to increase the risk of birth defects in infants, and its use while breastfeeding is not linked to growth problems in the youngsters, according to follow-up data of mothers and their children…
Quantum Biopharma is partnering with researchers at Massachusetts General Hospital in Boston on a clinical study to test a positron emission tomography (PET) tracer for monitoring changes in myelin content in people with multiple sclerosis (MS). The Phase 1 study (NCT04699747) is recruiting healthy adults and people…
No added benefit was found in increasing the dose of Genentech’s Ocrevus (ocrelizumab) — to two to three times the currently approved 600 mg dose — in slowing disability progression in adults with relapsing multiple sclerosis (MS), according to new data from a Phase 3 clinical study. The…
Fibrobiologics’ investigational cell therapy CYMS101 can significantly increase myelin production and promote myelin repair in a mouse model of multiple sclerosis (MS), the company has announced. The experimental therapy, which is made of connective tissue cells called fibroblasts, demonstrated benefits within seven weeks after both single and multiple infusions…
In an Army surveillance course I took in the spring of 2010, which I wrote about last year, I learned more than just the fact that I had a noticeable limp. For instance, on the first day, we had a class on simple ways to alter your appearance when…
The patient support program Cycle Vita, which assists patients throughout the process of medical prescriptions, is now available for people taking the multiple sclerosis (MS) medication Bafiertam (monomethyl fumarate). That’s according to Cycle Pharmaceuticals, in an announcement a few months after the company acquired Banner…
People with multiple sclerosis (MS) may receive less frequent infusions of rituximab without increasing their chances of relapse or disease progression, according to a real-world study from Norway. After receiving three doses at six-month intervals, extending the time between following doses to nine months is “a safe and effective…
I knew that starting my college journey in a a different city, less than a year after receiving my relapsing-remitting multiple sclerosis (RRMS) diagnosis, would be challenging because I didn’t fully understand what was happening in my body. Even though my college, the University of Texas at Austin,…
A small molecule that blocks the activity of a protein called TYK2 in the brain showed promise at reducing disease activity in mouse models of multiple sclerosis (MS), according to a study. The study was conducted by Neuron23, which is advancing a small molecule TYK2 inhibitor called NEU-627…
Recently, my work-life balance felt off, so I took the opportunity to house-sit a family farm. I needed the solitude — the peace and quiet — to recharge. While there, I watched a flock of 50 to 60 goldfinches gather at the bird feeders daily. Their communal nature fascinated me,…
The AdventHealth Neuroscience Institute is recruiting patients for a Phase 1b clinical trial testing IDP-023, an off-the-shelf cell-based treatment that Indapta Therapeutics is developing for primary or nonactive secondary progressive multiple sclerosis (MS). The company delayed the study’s expected launch in the second half of last…
Sexual dysfunction affects 80% of women in Iran with multiple sclerosis (MS), with older age and lower education levels seen as key risk factors, a study found. The study, ”The prevalence of sexual dysfunction and its contributors among the women with multiple sclerosis,” was published in BMC Women’s…
A researcher and neurologist at Penn Medicine in Philadelphia has won the 2025 John Dystel Prize for Multiple Sclerosis Research for his work in uncovering immune mechanisms of multiple sclerosis (MS), identifying disease biomarkers, and finding new avenues toward tailored medicine. The prize comes with a sculpture and…
From left, Adela Puente and her niece, Desiree Lama, spend time together in downtown San Antonio. (Photos courtesy of Desiree Lama) Day 31 of 31 This is Adela Puente’s story: Lama and Puente share a hug at Desiree’s college graduation. Being the youngest of six, I always wished…
A high dose cholecalciferol, a form of vitamin D, significantly reduced the risk of further disease activity in people with clinically isolated syndrome (CIS), published findings from a Phase 3 trial show. Vitamin D was similarly effective for reducing disease activity among a subgroup of participants who would…
Sheila Hofmeister and her husband, Rick, stand behind the wheelchair of their son Ben Hofmeister, whose three sons, Sterling, Jule, and Monte, are pictured from left to right. (Photos courtesy of Ben Hofmeister) Day 30 of 31 This is Sheila Hofmeister’s story: Note: Multiple Sclerosis News Today columnist…
Natasha Quariab relaxes in her garden in Amman, Jordan, in 2023. (Photos courtesy of Natasha Quariab) Day 29 of 31 This is Natasha Quariab’s story: I woke up and tried to move my right leg. Nothing. My heart pounded. This couldn’t be happening. Not here, alone in a snowy…
A multicenter Phase 2a clinical trial testing Tiziana Life Sciences’ foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS) has dosed the first patients enrolled at Yale MS Center. The Phase 2a study (NCT06292923) is assessing the treatment’s safety and efficacy against a placebo in…
Fampridine, which is approved to improve walking in people with multiple sclerosis (MS), and the disease-modifying therapy Ocrevus (ocrelizumab) seem to have the greatest benefits on MS walking abilities, according to a systematic review and meta-analysis of treatment options. The data align with previous findings for fampridine, which…
I despise theme parks, and I feel zero guilt about depriving my kids of Disneyland, Six Flags, and the general horror of standing in long lines to be terrorized. Why do I hate theme parks? It’s not the shameless commercialism, the overpriced food, or the fact that the tickets for…
Get regular updates to your inbox.
